Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis

Next Previous
Search
Trial Profile

A Phase 2b, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in Adults with Moderate-to-Severe Atopic Dermatitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rezpegaldesleukin (Primary)
  • Indications Atopic dermatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms REZOLVE-AD
  • Sponsors Nektar Therapeutics

Most Recent Events

  • 12 Mar 2025 According to a Nektar Therapeutics media release, topline data expected in the fourth quarter of this year.
  • 28 Jan 2025 Planned primary completion date changed from 30 May 2025 to 1 Jun 2025.
  • 10 Jan 2025 According to a Nektar Therapeutics media release, company is looking forward to announce the topline data from the 16week induction treatment period in this study in the second quarter of 2025.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top